Interleukin-1 beta signaling axis (IL-1β axis)

The Interleukin-1 beta (IL-1β) signaling axis is a fundamental pathway of the innate immune system that orchestrates the body's inflammatory response to pathogens and cellular damage (Dinarello, 2011). The axis is centered on the potent pro-inflammatory cytokine IL-1β, which is produced as an inactive precursor and requires processing by the NLRP3 inflammasome and caspase-1 for activation and secretion (NIH). Once released, mature IL-1β binds to the Interleukin-1 receptor type 1 (IL-1R1), leading to the recruitment of the IL-1 receptor accessory protein (IL-1RAcP) and the activation of downstream signaling pathways such as NF-κB and MAP kinases (UniProt). Chronic or excessive activation of this axis is implicated in a wide range of diseases, including autoinflammatory syndromes like gout and Cryopyrin-Associated Periodic Syndromes (CAPS), as well as cardiovascular conditions like atherosclerosis and recurrent pericarditis (Ridker et al., 2017). Therapeutic intervention typically involves the use of monoclonal antibodies, receptor antagonists, or decoy receptors to block IL-1β activity. While these therapies are highly effective in managing inflammatory symptoms, they are associated with an increased risk of serious infections due to the suppression of innate immune defenses (StatPearls).

Other names

IL-1 beta pathwayIL-1 signaling axisInterleukin-1 signaling pathwayIL-1B axis

Inhibition of the Interleukin-1 beta signaling axis is achieved through several pharmacological approaches: monoclonal antibodies (e.g., canakinumab) that bind and neutralize the mature IL-1 beta cytokine; recombinant receptor antagonists (e.g., anakinra) that competitively block the IL-1 receptor type 1 (IL-1R1); and soluble decoy receptors or traps (e.g., rilonacept) that sequester the cytokine to prevent receptor activation (Dinarello, 2011; NIH).